InvestorsObserver
×
News Home

Will Celldex Therapeutics, Inc. (CLDX) Stay at the Top of the Healthcare Sector?

Thursday, August 18, 2022 12:47 PM | InvestorsObserver Analysts

Mentioned in this article

Will Celldex Therapeutics, Inc. (CLDX) Stay at the Top of the Healthcare Sector?

Celldex Therapeutics, Inc. (CLDX) is around the top of the Healthcare sector according to InvestorsObserver. CLDX received an overall rating of 49, which means that it scores higher than 49% of stocks. Additionally, Celldex Therapeutics, Inc. scored a 78 in the Healthcare sector, ranking it higher than 78% of stocks in that sector.

Overall Score - 49
CLDX has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on CLDX!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Celldex Therapeutics, Inc. Stock Today?

Celldex Therapeutics, Inc. (CLDX) stock is trading at $33.80 as of 12:45 PM on Thursday, Aug 18, a loss of -$2.93, or -7.98% from the previous closing price of $36.73. The stock has traded between $33.70 and $36.65 so far today. Volume today is below average. So far 294,076 shares have traded compared to average volume of 639,057 shares. Click Here to get the full Stock Report for Celldex Therapeutics, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App